In addition, in a large analysis including more than 500 HR+ BC patients randomized to receive adjuvant tamoxifen vs. no adjuvant treatment, CD8+ T cells were found to be significantly associated with decreased RFS rates in both tamoxifen-treated and untreated cohorts, regardless of HER2 status. The gene discussed is CD8A; the disease is breast cancer.